Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-002: Adjuvant V940 (mRNA-4157) Plus Pembrolizumab in Resected Stage II-IIIB NSCLC
NCT06077760Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Jun 2030
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Intismeran autogene + Pembrolizumab with Placebo + Pembrolizumab (2 arms). Primary endpoint: Disease-Free Survival. Started Dec 2023; status: active, not recruiting.
02
Drugs
intismeran autogene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06077760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06077760.